Form 4: InMed Pharmaceuticals CEO Exercises Stock Options
SEC Form 4
Eric A. Adams, President and CEO of InMed Pharmaceuticals, exercised employee stock options on May 27, 2024.
Summary
- On May 27, 2024, Eric A. Adams, the President and CEO of InMed Pharmaceuticals Inc., exercised employee stock options.
- The transaction involved 1,139 common shares.
- The exercise price was $263.18 per option, converted from a Canadian dollar price of C$358.875 using an exchange rate of C$1.3636.
- Following the transaction, Adams directly owns 161,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option exercise, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock option exercises, common in publicly traded companies.
Stakeholder Impact
- The exercise of stock options by the CEO could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/27/2019 | Date exercisable for employee stock options |
| 05/27/2024 | Date of transaction: Eric A. Adams exercised employee stock options; Expiration date for employee stock options |
| 05/28/2024 | Date of signature |
Keywords
stock options, Form 4, InMed Pharmaceuticals, Eric A. Adams, derivative securities, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.